Shares of Avacta Group Plc (LON:AVCT – Get Free Report) shot up 11.2% during mid-day trading on Thursday . The company traded as high as GBX 50.65 ($0.63) and last traded at GBX 49.21 ($0.62). 1,038,627 shares were traded during trading, a decline of 56% from the average session volume of 2,346,237 shares. The stock had previously closed at GBX 44.25 ($0.55).
Avacta Group Stock Performance
The company has a market capitalization of £175.57 million, a price-to-earnings ratio of -547.44 and a beta of 1.12. The company has a 50 day moving average price of GBX 54.43 and a 200 day moving average price of GBX 57.25. The company has a debt-to-equity ratio of 63.54, a quick ratio of 4.96 and a current ratio of 1.29.
Insiders Place Their Bets
In other Avacta Group news, insider Tony Peter Gardiner sold 500,000 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of GBX 71 ($0.89), for a total value of £355,000 ($445,029.46). Corporate insiders own 32.90% of the company’s stock.
Avacta Group Company Profile
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms.
Featured Stories
- Five stocks we like better than Avacta Group
- The 3 Best Blue-Chip Stocks to Buy Now
- Tesla Investors Continue to Profit From the Trump Trade
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Market Cap Calculator: How to Calculate Market Cap
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.